Atezolizumab as the First Systemic Therapy Approved for Alveolar Soft Part Sarcoma.

With no other treatments that are FDA approved specifically for ASPS, and few demonstrating efficacy in the advanced setting, the approval of atezolizumab, including the first approval for pediatric patients, represents a landmark improvement to the therapeutic arsenal against this rare disease.